Clovis Oncology (CLVS) Given a $85.00 Price Target by Barclays Analysts
Barclays set a $85.00 price target on Clovis Oncology (NASDAQ:CLVS) in a report published on Tuesday, MarketBeat.com reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
A number of other equities research analysts also recently issued reports on CLVS. Morgan Stanley decreased their price target on shares of Clovis Oncology from $89.00 to $86.00 and set an overweight rating on the stock in a research note on Thursday, November 2nd. Stifel Nicolaus reiterated a buy rating and set a $125.00 price objective on shares of Clovis Oncology in a research report on Friday, November 3rd. Leerink Swann reiterated an outperform rating and set a $90.00 price objective (down previously from $107.00) on shares of Clovis Oncology in a research report on Wednesday, November 15th. ValuEngine cut shares of Clovis Oncology from a hold rating to a sell rating in a research report on Tuesday, December 5th. Finally, BidaskClub upgraded shares of Clovis Oncology from a strong sell rating to a sell rating in a research report on Saturday, December 9th. One analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have given a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $87.84.
Shares of Clovis Oncology (NASDAQ:CLVS) opened at $59.96 on Tuesday. The company has a quick ratio of 3.16, a current ratio of 7.69 and a debt-to-equity ratio of 0.77. Clovis Oncology has a 12 month low of $45.42 and a 12 month high of $99.45.
In other news, insider Gillian C. Ivers-Read sold 3,000 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $54.09, for a total value of $162,270.00. Following the transaction, the insider now directly owns 180,571 shares in the company, valued at $9,767,085.39. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Thorlef Spickschen sold 4,500 shares of the company’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $60.00, for a total transaction of $270,000.00. Following the completion of the transaction, the director now owns 16,618 shares in the company, valued at $997,080. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 22,500 shares of company stock worth $1,364,595. Company insiders own 12.50% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Capital Analysts LLC bought a new position in shares of Clovis Oncology in the third quarter worth about $111,000. Cypress Capital Management LLC WY grew its holdings in shares of Clovis Oncology by 272.7% in the third quarter. Cypress Capital Management LLC WY now owns 2,050 shares of the biopharmaceutical company’s stock worth $169,000 after purchasing an additional 1,500 shares during the last quarter. Commonwealth Equity Services Inc bought a new position in shares of Clovis Oncology in the third quarter worth about $239,000. First Republic Investment Management Inc. bought a new position in shares of Clovis Oncology in the third quarter worth about $251,000. Finally, BB&T Securities LLC bought a new position in shares of Clovis Oncology in the third quarter worth about $288,000.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/clovis-oncology-clvs-given-a-85-00-price-target-by-barclays-analysts/1904059.html.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.